A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)
Status:
NOT_YET_RECRUITING
Trial end date:
2032-04-09
Target enrollment:
Participant gender:
Summary
Researchers want to learn if MK-1084 given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation.
The goals of this study are to learn:
* How many people have the cancer respond (get smaller or go away) to MK-1084 alone or with cetuximab and how these responses compare
* About the safety of MK-1084 alone or with cetuximab and if people tolerate the treatments.